These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 11758580)
1. The biotechnology industry organization's view on Hatch-Waxman reform. Schmickel D Food Drug Law J; 1999; 54(2):241-2. PubMed ID: 11758580 [No Abstract] [Full Text] [Related]
2. Protecting the balance of Hatch-Waxman: understanding the industry's new dynamics for the 21st century. Schroeder RG; Papas P Food Drug Law J; 2001; 56(1):19-26. PubMed ID: 11942348 [No Abstract] [Full Text] [Related]
3. Navigating the Hatch-Waxman Act's safe harbor. Jones PB Food Drug Law J; 2002; 57(3):475-89. PubMed ID: 12710407 [No Abstract] [Full Text] [Related]
4. Old drugs, new uses: solving a Hatch-Waxman patent predicament. McPhie DC Food Drug Law J; 2004; 59(1):155-68. PubMed ID: 15190929 [No Abstract] [Full Text] [Related]
5. Overview of the Hatch-Waxman Act and its impact on the drug development process. Mossinghoff GJ Food Drug Law J; 1999; 54(2):187-94. PubMed ID: 11758572 [No Abstract] [Full Text] [Related]
8. Pharmaceutical patent life-cycle management after KSR v. Teleflex. Furrow ME Food Drug Law J; 2008; 63(1):275-320. PubMed ID: 18561462 [No Abstract] [Full Text] [Related]
9. Obviousness, hindsight and perspective: the impact of KSR v. Teleflex on biotech and pharmaceutical patents. Teitelbaum R; Cohen M Nat Biotechnol; 2007 Oct; 25(10):1105-6. PubMed ID: 17921990 [No Abstract] [Full Text] [Related]
10. Biotech patents-business as usual? Lawrence S Nat Biotechnol; 2008 Dec; 26(12):1326. PubMed ID: 19060861 [No Abstract] [Full Text] [Related]
11. Leading biotechnology companies quit the IBA. Gershon D Nature; 1990 Apr; 344(6266):481. PubMed ID: 2320118 [No Abstract] [Full Text] [Related]
12. FDA's role in administering the Hatch-Waxman Act. Malkin BJ Food Drug Law J; 1999; 54(2):211-4. PubMed ID: 11758575 [No Abstract] [Full Text] [Related]
13. The Hatch-Waxman Act during patent prosecution and beyond. Mahn TG Food Drug Law J; 1999; 54(2):233-6. PubMed ID: 11758578 [No Abstract] [Full Text] [Related]
19. 2004 update--180-day exclusivity under the Hatch-Waxman amendments to the federal Food, Drug, and Cosmetic Act. Lietzan EK Food Drug Law J; 2004; 59(4):459-63. PubMed ID: 15875350 [TBL] [Abstract][Full Text] [Related]
20. How would patent reform legislation in the United States impact the pharmaceutical industry? Williams AW Expert Opin Ther Pat; 2015 Feb; 25(2):131-3. PubMed ID: 25387953 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]